East
Amhurst, NY - Basem Goueli, MD, Ph.D., MBA, is being recognized by Continental
Who's Who as a Distinguished CEO in the Healthcare
field and in acknowledgment of his work at CancerLight, CancerClarity, and
Xbiotech.
Basem
Goueli is a seasoned healthcare professional and executive who recently started
two medical businesses, CancerLight and CancerClarity. He has been practicing
Hematology and Medical Oncology since 2012.
Dr.
Goueli completed a Bachelor of Science in Biochemistry/Genetics/Cell Biology at
the University of Minnesota in 1996. Subsequently, he obtained his Medical
Doctorate and Doctorate of Philosophy degree in Biochemistry at the Mayo Clinic
College of Medicine in 2005. Dr. Goueli completed his internal medicine residency
at George Washington University in 2008, during which he spent four months
training at the National Institutes of Health. Dr. Goueli did his fellowship in
Hematology and Medical Oncology and post-doctoral fellowship in biochemistry at
Stanford University from 2008-2012. He completed his Master of Business
Administration from the University of North Carolina at Chapel Hill in 2021.
Dr. Goueli has specialized training in business analytics, machine learning,
and artificial intelligence through coursework he completed at UNC and
MIT.
Dr.
Goueli is board certified in hematology, medical oncology, internal medicine,
and artificial intelligence in medicine. Since 2012, Dr. Goueli has trained in
hematology and medical oncology and directed three separate cancer institutes,
totaling 17 hospitals and 12 cancer centers. He was Director at St. Luke's
Regional Cancer Center from 2012-2018, Director of Hematology and Medical
Oncology at Covenant Health/Thompson Oncology Group in 2018. From 2019-2021,
Dr. Goueli was the Associate Chief of Hematology/Medical Oncology at the
University at Buffalo and Director of Hematology and Medical Oncology at Great
Lakes Cancer Care.
Dr.
Goueli has consulted for numerous companies, including Janssen, Astra Zeneca,
Blueprint, Genentech, and Xbiotech. He presently serves as the national medical
director for 3 Xbiotech oncology clinical trials.
In his
newest endeavors, Dr. Goueli began two companies still in the early stages of
development. He is the CEO and founder CancerLight in 2021, which is developing
an unprecedented patient education platform predicated on AI and machine
learning and a novel video-based paradigm.
Dr.
Goueli is also CEO and founder of CancerClarity, which performs pharmaceutical
and cancer center consulting and employs artificial intelligence/machine
learning algorithms in the clinical trial and precision medicine
arenas.
Dr.
Goueli is adept at all hematology and medical oncology disciplines. He has
published numerous publications in various diseases, including three in the
prestigious New England Journal of Medicine and two in Lancet. Dr. Goueli
considers himself a "full-stack" hematologist and medical oncologist.
He has a unique skill set that enables him to cross disciplines, including business,
AI/machine learning, medicine, basic research, etc. Dr. Goueli's leadership
style is predicated on empathy and accountability. His goal is to help as many
people as possible in the shortest time frame possible.
